Compare OSIS & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSIS | DYN |
|---|---|---|
| Founded | 1987 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 1997 | 2020 |
| Metric | OSIS | DYN |
|---|---|---|
| Price | $236.68 | $25.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $302.83 | $37.00 |
| AVG Volume (30 Days) | 170.4K | ★ 2.6M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.71 | N/A |
| Revenue | ★ $1,089,286,000.00 | N/A |
| Revenue This Year | $9.74 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $39.50 | ★ N/A |
| Revenue Growth | ★ 13.35 | N/A |
| 52 Week Low | $197.27 | $9.89 |
| 52 Week High | $311.72 | $26.62 |
| Indicator | OSIS | DYN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.41 |
| Support Level | N/A | $16.00 |
| Resistance Level | N/A | $26.62 |
| Average True Range (ATR) | 0.00 | 1.47 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 87.27 |
OSI Systems Inc is a designer and manufacturer of electronic systems and components for businesses in the homeland security, healthcare, defense, and aerospace markets. The firm is organized in three business segments: Security, which derives maximum revenue, provides security and inspection systems; Healthcare, which provides patient monitoring, diagnostic, cardiology, ventilation systems, and defibrillators; and Optoelectronics and Manufacturing, which provides specialized electronic components and manufacturing services for the Security and Healthcare segments and external original equipment manufacturers. The majority of the firm's revenue is generated in the United States, and the rest from Mexico, Europe, the Middle East and Africa, and the Asia Pacific regions.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.